Ms. Groves has served as one of our directors since March 2017. Most recently, Ms. Groves held multiple leadership roles at Stimwave, LLC, including serving as Chief Financial Officer and Chief Operating Officer, and served as a director of Stimwave Technologies, Inc. Previously, Ms. Groves served as the Chief Executive Officer of REVA Medical, Inc., a formerly publicly-traded medical device company focused on the bioresorbable polymer technologies for vascular applications. Prior to REVA Medical, she held various leadership positions at Medtronic, Inc. from 2002 to 2015, including Vice President and General Manager of AF Solutions, Cardiac Rhythm and Heart Failure division, where she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. Her experience at Medtronic included senior roles as Vice President of Quality and Regulatory for Medtronic s Cardiac Rhythm Disease Management (CRDM) and Vice President and General Manager for Patient Management CRDM. Ms. Groves currently serves on the Board of Directors of Fulgent Genetics, Inc., a publicly traded company providing technology-based therapeutic development and clinical diagnostics and several privately-held life science companies. Ms. Groves holds a B.S. in Pharmacy from the University of Florida and an M.B.A. from Harvard Graduate School of Business Administration. Ms. Groves qualifies as an audit committee financial expert under SEC rules, holds a CERT Certificate in Cybersecurity Oversight and completed A Director's Guide to AI: Strategy, Governance & Value Creation from the National Association of Corporate Directors (NACD). As a seasoned executive in the medical device industry, Ms. Groves has significant leadership experience and diverse business skill set with a global perspective. Her background includes management of rapid growth, financial turnaround, acquisition integration and significant and complex events with reputational impact (including FDA). She is an expert in enterprise risk assessment and mitigation and possesses functional experience in strategy, finance, sales, Afib, manufacturing operations and marketing matters which the Board considers as valuable skills for evaluating and improving the Company s competitive position as well as supporting the functions of the Board s various committees.